Compass Therapeutics, INC Form 4 insider transactions

Jonathan Anderman, Sr VP, Gen Counsel & Corp Sec of Compass Therapeutics, was granted stock options for 280,000 shares on February 11, 2025.

Director and 10% owner Carl L. Gordon acquired 40,000 stock options in Compass Therapeutics on February 11, 2025, according to a recent SEC Form 4 filing.

Director James P. Boylan of Compass Therapeutics acquires 40,000 stock options with an exercise price of $3.65 on February 11, 2025.

CEO Thomas Schuetz of Compass Therapeutics reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Compass Therapeutics CEO Thomas Schuetz sold 58,054 shares to cover tax obligations related to vesting restricted stock units.

Compass Therapeutics' CFO, Barry Shin, received 400,000 stock options and 400,000 restricted stock units on December 9, 2024, subject to vesting conditions.

Jonathan Anderman, Sr VP, Gen Counsel & Corp Sec of Compass Therapeutics, was granted stock options to purchase 300,000 shares.

Director James P. Boylan of Compass Therapeutics acquired stock options for 40,000 shares on March 8, 2024, vesting monthly starting April 8, 2024.